Kerendia Approved to Reduce CKD Progression, CV Risk in Patients With Diabetic Kidney Disease
The approval was based on data from the phase 3 FIDELIO-DKD trial.
Diagnosis & Disease Information
Soaanz Approved for Edema With Heart Failure, Renal Disease
Soaanz is a loop diuretic with an extended duration of action lasting approximately 6 to 8 hours.
Finerenone Improves Cardiovascular Outcomes in Patients With Diabetic Kidney Disease
The study evaluated finerenone in addition to standard of care in patients with chronic kidney disease and type 2 diabetes.
Dapagliflozin Reduces Risk for Kidney Events in IgA Nephropathy
In patients with IgA nephropathy, dapagliflozin significantly reduced the risk of CKD progression when added to ACEi/ARB therapy.
First COVID-19 Vaccine Dose Elicits Weak Antibody Response in Most KTRs
Investigators recommended close surveillance after COVID-19 vaccination of kidney transplant recipients and suggested the possibility that a third dose may be required in less responsive patients.
Terlipressin Bests Placebo in Type 1 Hepatorenal Syndrome
Terlipressin is more effective for reversal of HRS but is associated with more adverse events and death due to respiratory disorders
Conservative CKD-MBD Management at Dialysis Initiation on the Rise
Trends suggest that clinical practice could be driven heavily by providers’ preferences and beliefs, resulting in substantial practice variation.
Iron Replacement Therapy Triferic AVNU Now Available
Triferic is an iron maintenance therapy that delivers between 5 to 7mg of iron with every hemodialysis treatment and maintains hemoglobin without increasing ferritin.
Lupkynis Approved for Active Lupus Nephritis
The approval was based on data from the pivotal phase 3 AURORA and phase 2 AURA-LV studies.
MPR Weekly Dose Podcast Episode 64
This week we have news of the neutralizing response of the Pfizer-BioNTech vaccine to the new COVID-19 variant; A trial investigated ravulizumab in adults with severe COVID is halted; A rapid blood test for concussions gets the all clear; A novel treatment for chronic kidney disease in patients with type 2 diabetes; And the drug manufacturer Fresenius Kabi announces a voluntary recall of one lot of an NSAID treatment.
